Evidence map›Paper›PMID 42359758›Full record

ArticleRadiology and oncology2026

Electroporation as a strategy to improve the efficacy of chemotherapy in neuroblastoma: an in vitro study.

Jonathan J Neville, Laura Privitera, Jingchen Sun, Renata Da Costa Magueta, Piotr Golda, Adam C Sedgwick, Paolo De Coppi, Ismael Diez Perez, Premal A Patel, John Anderson and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology and oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jonathan J Neville1University College London, Great Ormond Street Institute of Child Health, London, UK.
Laura Privitera1University College London, Great Ormond Street Institute of Child Health, London, UK.
Jingchen Sun3Division of Biosciences, Faculty of Life Sciences, University College London, London, UK.
Renata Da Costa Magueta4London Metallomics Facility, King's College London, London, UK.
Piotr Golda4London Metallomics Facility, King's College London, London, UK.
Adam C Sedgwick5Department of Chemistry, King's College London, London, UK.
Paolo De Coppi1University College London, Great Ormond Street Institute of Child Health, London, UK.
Ismael Diez Perez5Department of Chemistry, King's College London, London, UK.
Premal A Patel6Interventional Radiology, Radiology Department, Great Ormond Street Hospital, London, UK.
John Anderson1University College London, Great Ormond Street Institute of Child Health, London, UK.
Stefano Giuliani1University College London, Great Ormond Street Institute of Child Health, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReversible electroporation involves the use of pulsed electric fields to temporarily disrupt and permeabilise cell membranes. Electroporation combined with chemotherapy - electrochemotherapy (ECT) - increases tumour cell permeability to chemotherapeutic drugs and enhances their effect. We investigated the efficacy of electroporation and cisplatin as a treatment for neuroblastoma MATERIALS AND

methodsThree immortalised neuroblastoma cell lines were exposed to eight 1 ms square wave pulses of 0-0.93 kV/cm electric fields in the presence of propidium iodide and reversible electroporation was identified by detecting live propidium iodide positive cells by flow cytometry. Intracellular cisplatin and olaparib levels after electroporation were investigated by measuring intracellular platinum via inductively coupled plasma mass spectrometry and by quantifying a fluorescent olaparib with flow cytometry. Cells were exposed to electroporation in the presence of cisplatin and olaparib, and cell death was quantified by flow cytometry. Presence of DNA damage was evaluated by quantifying γ-H2AX immunofluorescence.

resultsReversible electroporation (0.74 kV/cm) increased intracellular cisplatin and olaparib levels. Electroporation with cisplatin (1-100 μM) significantly reduced cell viability compared to cisplatin treatment in all cell lines. The addition of olaparib (5 μM) modestly potentiated the effects of cisplatin and electroporation. DNA damage was significantly higher following treatment with a combination of electroporation, cisplatin and olaparib, compared to each treatment alone.

conclusionsElectroporation with cisplatin appears effective against neuroblastoma

Indexed as

Antineoplastic AgentsCisplatinElectrochemotherapyElectroporationNeuroblastomaPhthalazinesPiperazinesCell Line, TumorDNA DamageFlow CytometryHumansAntineoplastic AgentsCisplatinolaparibPhthalazinesPiperazinescisplatinelectroporationneuroblastomaoncologypaediatricspoly-(ADP ribose) polymerase 1

Identifiers

PMID42359758
PMCPMC13307008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.